Daiichi Sankyo on Friday named Dr. John Tsai as its new global head of research and development, signaling a high-stakes push to accelerate its industry-leading oncology pipeline. Tsai will officially succeed Dr. Ken Takeshita, on April 1.
Based out of Daiichi Sankyo’s dual global hubs in Tokyo and Basking Ridge, New Jersey, Tsai enters the role as the company embarks on its next five-year business plan. His primary mission: scaling the “next wave” of the company’s proprietary DXd Antibody Drug Conjugate (ADC) technology, which has already revolutionized treatment for HER2-positive cancers.
Tsai is widely regarded as one of the most prolific drug developers in the pharmaceutical industry. He joins Daiichi Sankyo from the venture capital firm Syncona Investment Management, but he is best known for his transformative tenure as president of Global Drug Development and chief medical officer at Novartis.
During his career, Tsai has overseen:
- 160 new projects and more than 500 clinical trials.
- 15 global drug approvals, including pioneers in gene therapy and radioligand therapy.
- Senior leadership roles at Amgen (chief medical officer) and Bristol Myers Squibb (head of late phase development).
“John Tsai will bring unique expertise as we execute our next five-year business plan and beyond,” Hiroyuki Okuzawa ,president and CEO of Daiichi Sankyo said. “His leadership in driving innovation will be a formidable addition as we pursue cutting-edge science.”
Tsai inherits an R&D organization transformed by Takeshita. Over the last five years, Takeshita successfully positioned Daiichi Sankyo as a global oncology leader, largely through the success of ENHERTU® and the expansion of a pipeline that now includes five late-stage DXd ADCs.
Just this week, the company saw the European Medicines Agency validate a major application for ENHERTU in early breast cancer settings—a testament to the momentum Tsai is expected to maintain.
The appointment reinforces Basking Ridge as a critical center for global pharmaceutical decision-making. As the U.S. headquarters for Daiichi Sankyo, the New Jersey site co-locates commercial and development divisions, allowing for seamless collaboration between R&D teams and global market strategists.
Tsai, who holds an Electrical Engineering degree from Washington University and an MD from the University of Louisville, is known for his “patient-first” philosophy, often mapping clinical development backward from the specific unmet needs of those in the hospital.
“Joining Daiichi Sankyo at such a pivotal time is both an honor and an exciting opportunity,” Tsai said. “I look forward to building on this legacy to further drive innovation for patients.”
